TRAW

+ Watchlist + Portfolio

Traws Pharma, Inc.

Regulated industry Physical products Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.54
52-Week Range: $0.43 – $3.27
Market Cap: $8.74M
P/E (TTM): —
EPS (TTM): -1.71
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 5.12
PEG Ratio: —
Return on Equity: -433.36%
Return on Assets: -99.40%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 0.93
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-13.33M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $3.72M

TRAW Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$226.00K	$226.00K	$226.00K	$2.79M
Research & Development	$11.41M	$11.43M	$12.85M	$12.14M
Selling, General & Admin	$8.45M	$9.09M	$12.29M	$8.52M
Operating Expenses	$19.85M	$20.52M	$25.14M	$20.66M
Operating Income	-$19.63M	-$20.30M	-$24.91M	-$17.88M
EBITDA	-$19.61M	-$20.28M	-$24.90M	-$17.81M
Pretax Income	-$18.96M	-$18.95M	-$166.52M	$9.17M
Net Income	-$18.96M	-$18.95M	-$166.52M	$9.17M
Diluted EPS	-22.75	-22.57	-35.21	0.82
Diluted Shares	836329	839554	1.55M	8.38M

TRAW Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$38.76M	$20.82M	$21.34M	$3.82M
Receivables	$29.00K	$18.00K	$1.76M	$3.79M
Current Assets	$39.35M	$22.66M	$24.95M	$7.98M
Total Assets	$39.37M	$22.68M	$24.96M	$10.62M
Current Liabilities	$8.05M	$9.22M	$11.53M	$11.15M
Total Liabilities	$11.06M	$12.01M	$56.59M	$11.25M
Retained Earnings	-$463.68M	-$482.63M	-$649.15M	-$639.98M
Shareholders' Equity	$28.31M	$10.67M	-$31.63M	-$629.00K
Working Capital	$31.30M	$13.44M	$13.42M	-$3.17M

TRAW Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.29M	-$17.93M	-$29.79M	-$18.18M
Capital Expenditure	—	-$14.00K	—	-$2.58M
Free Cash Flow	-$16.29M	-$17.95M	-$29.79M	-$20.77M
Depreciation & Amortisation	$14.00K	$16.00K	$12.00K	$61.00K
Stock-Based Compensation	$1.17M	$1.30M	$1.39M	$728.00K
Investing Cash Flow	$0.00	-$14.00K	-$3.65M	-$2.58M
Financing Cash Flow	$0.00	$0.00	$33.98M	$3.20M
Net Change in Cash	-$16.29M	-$17.95M	$536.00K	-$17.57M

TRAW Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$57.00K	$2.73M	$0.00	$0.00	$0.00	$0.00
Research & Development	$2.51M	$2.29M	$2.31M	$5.04M	$4.91M	$1.10M
Selling, General & Admin	$2.75M	$1.69M	$1.74M	$2.33M	$2.03M	$3.48M
Operating Expenses	$5.26M	$3.98M	$4.05M	$7.37M	$6.95M	$3.17M
Operating Income	-$5.20M	-$1.25M	-$4.05M	-$7.37M	-$6.95M	-$3.17M
EBITDA	-$5.20M	-$1.25M	-$4.04M	-$7.32M	-$6.90M	-$3.13M
Pretax Income	$21.49M	-$915.00K	-$3.96M	-$7.44M	-$7.11M	-$3.05M
Net Income	$21.49M	-$915.00K	-$3.96M	-$7.44M	-$7.11M	-$3.05M
Diluted EPS	2.09	-0.11	-0.34	—	-0.53	-0.16
Diluted Shares	7.22M	5.82M	8.82M	—	10.64M	15.86M

TRAW Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$15.94M	$13.08M	$6.42M	$3.82M	$3.13M	$5.02M
Receivables	$1.65M	$1.32M	$1.99M	$3.79M	$1.69M	$3.45M
Current Assets	$18.86M	$15.37M	$9.63M	$7.98M	$5.67M	$9.02M
Total Assets	$19.06M	$15.62M	$12.44M	$10.62M	$8.16M	$11.47M
Current Liabilities	$10.40M	$7.35M	$7.89M	$11.15M	$13.21M	$9.73M
Total Liabilities	$13.06M	$7.36M	$7.90M	$11.25M	$13.47M	$9.78M
Retained Earnings	-$627.66M	-$628.58M	-$632.54M	-$639.98M	-$647.09M	-$650.14M
Shareholders' Equity	$6.00M	$8.26M	$4.54M	-$629.00K	-$5.31M	$1.69M
Working Capital	$8.46M	$8.02M	$1.74M	-$3.17M	-$7.54M	-$712.00K

TRAW Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$5.44M	-$5.98M	-$4.01M	-$2.76M	-$2.58M	-$7.50M
Free Cash Flow	-$5.44M	-$5.98M	-$6.60M	-$2.76M	-$2.58M	-$7.50M
Depreciation & Amortisation	$1.00K	$1.00K	$15.00K	$44.00K	$44.00K	$44.00K
Stock-Based Compensation	$161.00K	$105.00K	$135.00K	$327.00K	$634.00K	$816.00K
Investing Cash Flow	—	—	-$2.58M	$0.00	—	—
Financing Cash Flow	$13.00K	$3.10M	-$62.00K	$158.00K	$1.90M	$9.39M
Net Change in Cash	-$5.42M	-$2.88M	-$6.66M	-$2.60M	-$679.00K	$1.89M

Market Snapshot

About

Traws Pharma is a clinical-stage biopharmaceutical company developing treatments for neurological and psychiatric disorders. The company focuses on novel therapeutic approaches for conditions including depression, anxiety, and neurodegenerative diseases. Traws is advancing multiple drug candidates through preclinical and clinical development.